Fenretinide in Treating Patients With Refractory or Relapsed Hematologic Cancer
Status:
Completed
Trial end date:
2017-04-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy, such as fenretinide, work in different ways to stop
the growth of cancer cells, either by killing the cells or by stopping them from dividing.
Giving fenretinide in a different way may kill more cancer cells.
PURPOSE: This phase I trial is studying the side effects and best dose of intravenous
fenretinide in treating patients with refractory or relapsed hematologic cancer.